Cardiometabolic Conditions

AI Built for the Full Spectrum of Cardiometabolic Care

A unified platform to address cardiometabolic complexities and critical comorbidities.

Get a Demo
Conditions
Impact
Industry Leadership
Jump to
Conditions

A Foundation for All Health

Hypertension

Heart Failure

Chronic kidney disease (CKD)

Sleep Apnea

Fatty Liver Disease & Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Graphic depicting the letter "W" at the center, connected to icons representing health conditions
Impact

Beyond silos: A total health solution for interconnected
cardiometabolic
risks

Facing a global rise in comorbidities and undiagnosed risk, Welldoc serves as the essential bridge to stop progression and simplify the management of interconnected conditions.
$1.54 billion

adults worldwide now meet the criteria for metabolic syndrome1

$30 billion

estimated avoidable U.S. healthcare spending annually due to fragmented cardiometabolic care

45%

increased chance of developing cardiovascular disease due to suboptimal sleep3

1 in 5 adults

with high blood pressure also have CKD in the U.S.4

1 in 3 adults

with diabetes also have CKD in the U.S.4

75%

of MASH cases remain undiagnosed5

Industry Leadership

Pioneering Cardiometabolic Research and AI

With over 60 clinical publications focused on cardiometabolic health, Welldoc leads the industry in developing next-generation solutions focused on the complexities of cardiometabolic conditions by:

Harnessing the power of next generation real-time sensor data
Leveraging innovative technology to build deeper health insights.
Understanding engagement patterns to address individual needs

Redefine cardiometabolic health at scale

Schedule a personalized demo to see how Welldoc’s integrated platform delivers a holistic approach to health for your entire population.

Get a DemoTalk to Sales
Screen displaying a health app interface with a prompt to sync health data and daily entry options.
Gradient design featuring a black background and a curved purple shape on the right.
References
  1. Yao, J., Wang, Y., Zhang, X., et al. (2025). Global, regional, and national burden of metabolic dysfunction-associated steatotic liver disease and its trends from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021. Nature Communications, 16(1), 1234. https://doi.org/10.1038/s41467-025-67268-5
  2. Bjornson, A., Szabo, S., Donato, B., Gardner, M., & Kuti, E. (2025). Prevalence of obesity-related multimorbidity and its health care costs among adults in the United States. Journal of Managed Care & Specialty Pharmacy, 31(3), 179–189. https://doi.org/10.18553/jmcp.2025.31.2.179
  3. Miezah, D., Srisoem, C., Ansong, R., Hinneh, T., Marfo, R., Abubakari, M., & Song, Q. (2026). Association between physical activity, sleep, and hypertension among U.S. middle-aged and older adults: Insights from NHANES. American Journal of Lifestyle Medicine. https://doi.org/10.1177/15598276261419397
  4. Centers for Disease Control and Prevention. (2024, May 15). Risk factors for chronic kidney disease. U.S. Department of Health and Human Services. https://www.cdc.gov/kidney-disease/risk-factors/index.html 
  5. American Liver Foundation. (2024). MASH/NASH: The silent epidemic. https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-steatohepatitis-nash/